Three different prognostic subgroups have been described depending on tumor localization and type of fusion gene, with (i) the best median OS in patients with non-thoracic non-BRD4:NUTM1 fusion carcinoma (36.5 months from initial cancer diagnosis), (ii) a median prognosis for non-thoracic disease with BRD4::NUTM1 fusion (10 months) and (iii) the worst prognosis (4.4 months) in patients with thoracic disease onset, independent of the fusion gene partner (2). The gene discussed is NUTM1; the disease is carcinoma.